Table of contents
- Manufacture, marketing and sale
- General Court annuls EMA decision refusing to validate application for orphan designation (Shire Pharmaceuticals Ireland Ltd v EMA)
- Innovate UK to invest £10m in antimicrobial resistance projects
- Brexit
- MLex Special Report: Rival Visions of a Brexit Deal
- Brexit—European Council adopts guidelines on future EU-UK relationship
- EU Commission sets out position on IP rights post-Brexit
- Disputes and regulatory enforcement
- Ombudsman finds European Medicines Agency refusal to identify company was ‘maladministration’
- IP
More sections of this document available when you sign-in to Lexis+ or register for a free trial.
Article summary
This week’s edition of Life Sciences highlights includes details of the General Court case Shire Pharmaceuticals Ireland Ltd v EMA concerning an application for orphan designation, news of The European Ombudsman’s decision that EMA’s refusal to identify a company that asked for public access to a report on a drug constituted maladministration, and the latest updates on Brexit, including the position on IP rights in the latest iteration of the draft withdrawal agreement.
To continue reading this news article, as well as thousands of others like it, sign in with LexisNexis or register for a free trial